The stock of Cerecor Inc (NASDAQ:CERC) hit a new 52-week high and has $5.47 target or 6.00% above today’s $5.16 share price. The 8 months bullish chart indicates low risk for the $52.18 million company. The 1-year high was reported on Nov, 22 by Barchart.com. If the $5.47 price target is reached, the company will be worth $3.13M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 12,931 shares traded hands. Cerecor Inc (NASDAQ:CERC) has risen 51.33% since April 20, 2016 and is uptrending. It has outperformed by 46.77% the S&P500.
According to Zacks Investment Research, “Cerecor, Inc. is a biopharmaceutical company which focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company’s portfolio of clinical and preclinical candidates consists of CERC-301, CERC-501 and CERC-406. CERC-301; adjunctive antidepressant for the treatment of patients with major depressive disorder; CERC-501, for co-occurring psychiatric and substance use disorders and CERC-406, for the treatment of residual cognitive impairment symptoms. Cerecor, Inc. is headquartered in Baltimore, Maryland.”
More notable recent Cerecor Inc (NASDAQ:CERC) news were published by: Marketwatch.com which released: “Cerecor Inc.” on November 22, 2013, also Businesswire.com with their article: “Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in …” published on August 29, 2016, Businesswire.com published: “Cerecor Inc. Appoints Thomas Aasen to Board of Directors” on January 12, 2016. More interesting news about Cerecor Inc (NASDAQ:CERC) were released by: Businesswire.com and their article: “Cerecor Inc. Names Uli Hacksell, Chairman of Cerecor and Former CEO of ACADIA …” published on December 21, 2015 as well as Reuters.com‘s news article titled: “BRIEF-Cerecor Inc – files for $75 million mixed shelf offering” with publication date: November 08, 2016.
CERC Company Profile
Cerecor, Inc., incorporated on January 31, 2011, is a clinical stage biopharmaceutical company. The Firm is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Firm has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Firm owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme that is critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. The Company’s COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT found within the central nervous system. The Company’s COMTi platform includes compounds with varying degrees of selectivity of peripheral versus brain COMT inhibition, including some that work on both peripheral and brain COMT, and some that work primarily on brain COMT.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.